Remove Marketing Remove Pharmaceuticals Remove Pharmacy Remove Webinar
article thumbnail

Hospitals Are Relying More on PBMs to Manage Manufacturers' 340B Contract Pharmacy Restrictions: DCI's 2024 Market Analysis (rerun)

Drug Channels

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The 340B contract pharmacy market shows little sign of slowing down. For an updated look at what’s next for the 340B contract pharmacy market, join Adam J.

article thumbnail

The 340B Drug Pricing Program: Trends, Controversies, and Outlook (NEW Live Video Webinar)

Drug Channels

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook This event will be broadcast live on Friday, June 21, 2024, from 12:00 p.m. Pharmacies and Pharmacy Benefit Managers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Five (or Maybe Six?) Reasons that the Largest PBMs Operate Group Purchasing Organizations

Drug Channels

In recent years, each of these companies has launched new group purchasing organizations (GPOs) to further consolidate the number of covered lives in rebate negotiations with pharmaceutical manufacturers. Today, I examine these PBM-owned GPOs and then speculate on five plausible explanations for their existence. to 1:30 p.m.

article thumbnail

Unlocking Access: Direct-to-Patient Cash Solutions for Pharma Manufacturers

Fierce BioTech

This webinar will explore innovative Direct-to-Patient cash solutions as a way to improve accessibility, convenience, and patient outcomes. Don't miss this opportunity to learn how pharma organizations can retain market share, increase overall profitability and boost their brand's gross to net. Click here to login.

article thumbnail

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us) (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Note that the forecasts below did not account for policy changes that could further reduce pharmaceuticals' share of U.S. healthcare spending. healthcare spending.

article thumbnail

Who Will Pay for Prescription Drugs in 2030? (Hint: It’s Us)

Drug Channels

As you will see below, outpatient prescription drugs dispensed by retail and mail pharmacies are projected to remain a small share (8.4%) of total U.S. What’s more, taxpayers—via Medicare and Medicaid—will continue to crowd out the private insurance market. healthcare spending. healthcare spending growth. healthcare spending growth.

article thumbnail

Specialty Pharmacy’s Explosive 340B Growth

Drug Channels

The 340B Drug Pricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others. As you will see below, mail and specialty pharmacies’ purchases of products that are eligible for 340B discounts have grown by an incredible 56% per year since 2017.